FDx Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

FDx Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,476	Closed	-$215K	–	644
2023 Q2	$215K	Buy	+2,476	New	+$233K	0.01%	700
2021 Q1	–	Sell	-2,709	Closed	-$238K	–	769
2020 Q4	$238K	Buy	+2,709	New	+$215K	0.01%	638
2020 Q3	–	Sell	-9,908	Closed	-$1.22M	–	610
2020 Q2	$1.22M	Buy	9,908 +2,369	+31%	+$235K	0.06%	197
2020 Q1	$637K	Buy	+7,539	New	+$650K	0.04%	261

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FDx Advisors's BMRN Position: Q3 2023 in Review

FDx Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 2,476 shares — an estimated $215K sold.

FDx Advisors first reported a position in BMRN in Q1 2020 and held it in 4 quarters. The position peaked at $1.22M in Q2 2020. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

FDx Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
FDx Advisors sold 2,476 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $215K.
FDx Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 4 quarters.
FDx Advisors's BioMarin Pharmaceuticals position peaked at $1.22M in Q2 2020.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on FDx Advisors's 13F filing for Q3 2023, filed 2 Nov 2023.